These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17214355)

  • 1. Survival markers related to bone metastases in prostate cancer.
    Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
    Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
    Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
    Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
    Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
    Wu ZQ; Zhang Y; Xie E; Song WJ; Yang RX; Yan CJ; Zhang BF; Xu HG
    PLoS One; 2016; 11(1):e0147554. PubMed ID: 26800211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
    Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
    Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
    Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
    Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
    Halleen JM
    Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
    Chao TY; Wu YY; Janckila AJ
    Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
    Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
    Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
    Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
    Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.